Changes in Peak Respiratory Flow and Quality of Life during Nebivolol Therapy

Background: Nebivolol is a highly cardioselective β₁-adrenoceptor antagonist with proven efficacy and safety in the treatment of hypertension. This study aimed to specifically address the effects of nebivolol on lung function and quality of life in patients suffering from mild to moderate hypertension. Objectives: The study assessed the effects of nebivolol, taken alone or in combination with other antihypertensives for 12 weeks, on peak respiratory flow, libido, general health, and physical condition. The effects on blood pressure and heart rate were also determined. Methods: A total of 367 patients suffering from mild to moderate hypertension were enrolled in 93 private general practices. Changes in peak respiratory flow, blood pressure, and heart rate were recorded after 4 and 12 weeks. A questionnaire on items of sexual function, physical energy, and general health elicited the patients’ perception of their quality of life. Safety was assessed on the basis of adverse events. Results: After 4 and 12 weeks, peak respiratory flow was significantly increased in patients receiving nebivolol alone (p < 0.01). Diastolic blood pressure (p < 0.01), systolic blood pressure (p < 0.01), and heart rate (p < 0.01) were significantly lowered during treatment. Moreover, nebivolol treatment (alone or in combination with other antihypertensives) statistically significantly improved libido, breathlessness, and energy level (p < 0.05). Conclusion: The favourable effect on peak respiratory flow, coupled with an improved quality of life, renders this cardioselective β₁-blocker useful in the treatment of essential hypertension in the general practice setting.